On May 27, 2026, OSR Holdings, Inc. entered into an agreement to buy VXM01 intellectual property from its subsidiary Vaximm AG for $30 million, linked to a prior licensing agreement for cancer immunotherapy. This is a significant event as it enhances the company's direct ownership of valuable assets and potential future revenue from the project.